{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:23:01Z","timestamp":1792516981633,"version":"4.5.0"},"reference-count":151,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory arthritis associated with psoriasis, affecting joints, entheses, and the axial skeleton. While primary care providers and dermatologists frequently encounter psoriasis (PsO), early recognition of PsA remains critical to preventing irreversible joint damage. This paper is written to provide a comprehensive overview of PsA, beginning with a clinical case that highlights diagnostic and therapeutic challenges. In this review, the epidemiology of PsA will be discussed, emphasizing its prevalence and risk factors among patients with PsO. The discussion extends to the underlying pathogenesis, focusing on genetic predisposition, environmental triggers, and key cytokines, including TNF-\u03b1, IL-17, and IL-23, that have become targets for advanced therapeutics. The clinical features of PsA are explored in detail, including peripheral and axial arthritis, enthesitis, dactylitis, and extra-articular manifestations. Diagnostic approaches are discussed, with a focus on the Classification Criteria for Psoriatic Arthritis (CASPAR) and Moll &amp; Wright criteria. Additionally, we examine screening tools designed to facilitate early detection in dermatology clinics. Diagnostic modalities, including imaging and serologic markers, are reviewed. Finally, we explore the evolving landscape of PsA treatment, spanning conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic agents (bDMARDs), and targeted synthetic DMARDs (tsDMARDs). Given the increasing availability of cytokine-targeted therapies, an interdisciplinary approach between dermatologists and rheumatologists is essential for optimizing outcomes in PsA patients. Patients with PsA are cared for by rheumatologists, dermatologists, and primary care providers who help manage the comorbidities associated with PsA. By bridging primary care, dermatology, and rheumatology in the care of PsA, this paper aims to enhance understanding of PsA for facilitating early identification and timely intervention for improved patient care.<\/jats:p>","DOI":"10.3390\/jcm14228151","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:55:31Z","timestamp":1763556931000},"page":"8151","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Psoriatic Arthritis: From Diagnosis to Treatment"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7579-8560","authenticated-orcid":false,"given":"Renuka","family":"Kannappan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Temple University Hospital, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8323-6853","authenticated-orcid":false,"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Temple University Hospital, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Jefferson-Einstein Hospital, Philadelphia, PA 19141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Brent","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Temple University Hospital, Philadelphia, PA 19140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kez325","article-title":"The many faces of psoriatic arthritis: Their genetic determinism","volume":"59","author":"Winchester","year":"2020","journal-title":"Rheumatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/BOR.0000000000000155","article-title":"Targeting extra-articular manifestations in PsA: A closer look at enthesitis and dactylitis","volume":"27","author":"Siegel","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101692","DOI":"10.1016\/j.berh.2021.101692","article-title":"The epidemiology of psoriatic arthritis: A literature review","volume":"35","author":"Karmacharya","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care Res"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","first-page":"127","article-title":"Psoriatic arthritis (PSA)\u2014An analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"QJM Int. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","article-title":"The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics","volume":"24","author":"Christophers","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/acr.20401","article-title":"Incidence of arthritis in a prospective cohort of psoriasis patients","volume":"63","author":"Eder","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3899\/jrheum.201123","article-title":"Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis","volume":"48","author":"Belman","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/acr.20496","article-title":"Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis","volume":"63","author":"Eder","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","article-title":"From Psoriasis to Psoriatic Arthritis: Decoding the Impact of Treatment Modalities on the Prevention of Psoriatic Arthritis","volume":"11","author":"Watad","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/ard-2023-224965","article-title":"Mortality in patients with psoriatic arthritis in Sweden: A nationwide, population-based cohort study","volume":"83","author":"Exarchou","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","article-title":"Concepts of pathogenesis in psoriatic arthritis: Genotype determines clinical phenotype","volume":"17","author":"FitzGerald","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lee, B.W., and Moon, S.J. (2023). Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202306.2029.v1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41584-020-00507-9","article-title":"Applying precision medicine to unmet clinical needs in psoriatic disease","volume":"16","author":"Jadon","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: A critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s12325-023-02475-4","article-title":"Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials","volume":"40","author":"Kavanaugh","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101694","DOI":"10.1016\/j.berh.2021.101694","article-title":"Pathogenesis of psoriatic arthritis","volume":"35","author":"Stober","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.2854","article-title":"Primed for inflammation: Enthesis-resident T cells","volume":"18","author":"Lories","year":"2012","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3899\/jrheum.210434","article-title":"Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics","volume":"48","author":"Gladman","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3899\/jrheum.141545","article-title":"Psoriatic Arthritis Mutilans: Clinical and Radiographic Criteria. A Systematic Review","volume":"42","author":"Haddad","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2020.05.089","article-title":"Axial psoriatic arthritis: An update for dermatologists","volume":"84","author":"Gottlieb","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: An update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.130163","article-title":"Dactylitis in psoriatic arthritis: Prevalence and response to therapy in the biologic era","volume":"40","author":"Gladman","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/art.39458","article-title":"Review: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment","volume":"68","author":"Kehl","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2021-220964","article-title":"Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis","volume":"81","author":"Dubash","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","first-page":"771","article-title":"Epidemiology and clinical characteristics of psoriatic arthritis-related uveitis in Madrid, Spain","volume":"43","author":"Ventas","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.1780221230","article-title":"Arthritis and allied conditions","volume":"22","author":"Ball","year":"1979","journal-title":"Arthritis Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum."},{"key":"ref_39","unstructured":"Calin, A. (1984). Psoriatic Arthropathy. Spondyloarthropathies, Grune and Stratton."},{"key":"ref_40","first-page":"446","article-title":"Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients","volume":"66","author":"Crognier","year":"1999","journal-title":"Rev. Rhum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/1529-0131(199906)42:6<1080::AID-ANR2>3.0.CO;2-7","article-title":"Psoriatic arthritis: A unified concept twenty years on","volume":"42","author":"McGonagle","year":"1999","journal-title":"Arthritis Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1136\/ard.2004.032318","article-title":"Classification and diagnostic criteria for psoriatic arthritis","volume":"64","author":"Helliwell","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1002\/art.34536","article-title":"Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis","volume":"64","author":"Coates","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/art.23018","article-title":"Classification criteria in rheumatic diseases: A review of methodologic properties","volume":"57","author":"Johnson","year":"2007","journal-title":"Arthritis Care Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.23104","article-title":"Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis","volume":"57","author":"Chandran","year":"2007","journal-title":"Arthritis Care Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11926-010-0113-2","article-title":"Development of screening tools to identify psoriatic arthritis","volume":"12","author":"Dominguez","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/ard.2008.089441","article-title":"Development and initial validation of a screening questionnaire for psoriatic arthritis: The Toronto Psoriatic Arthritis Screen (ToPAS)","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2007.04.001","article-title":"The PASE questionnaire: Pilot-testing a psoriatic arthritis screening and evaluation tool","volume":"57","author":"Husni","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00403-009-0981-3","article-title":"Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire","volume":"301","author":"Dominguez","year":"2009","journal-title":"Arch. Dermatol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.140857","article-title":"Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2)","volume":"42","author":"Tom","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_52","first-page":"469","article-title":"Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: The Psoriasis Epidemiology Screening Tool (PEST) questionnaire","volume":"27","author":"Ibrahim","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/rheumatology\/key314","article-title":"Psoriatic arthritis screening: A systematic review and meta-analysis","volume":"58","author":"Iragorri","year":"2019","journal-title":"Rheumatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjd.14929","article-title":"Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study)","volume":"176","author":"Mishra","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_55","first-page":"127","article-title":"A validation study of the Simple Psoriatic Arthritis Screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis","volume":"36","author":"Salaffi","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"101690","DOI":"10.1016\/j.berh.2021.101690","article-title":"Imaging in psoriatic arthritis: Status and recent advances","volume":"35","author":"Mathew","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102061","DOI":"10.1016\/j.berh.2025.102061","article-title":"Imaging in the diagnosis and management of peripheral psoriatic arthritis: Update and recent advances","volume":"39","author":"Mathew","year":"2025","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_58","first-page":"S31","article-title":"The involvement of the spine in psoriatic arthritis","volume":"33","author":"Baraliakos","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Bonfiglioli, K.R., Lopes, F.O.d.A., de Figueiredo, L.Q., Ferrari, L.F.F., and Guedes, L. (2024). Ultrasonographic Insights into Peripheral Psoriatic Arthritis: Updates in Diagnosis and Monitoring. J. Pers. Med., 14.","DOI":"10.3390\/jpm14060550"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3899\/jrheum.2023-0091","article-title":"Ultrasound in the Management of Patients With Psoriatic Arthritis: Systematic Literature Review and Novel Algorithms for Pragmatic Use","volume":"51","author":"Gouze","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1759720x241288060","DOI":"10.1177\/1759720X241288060","article-title":"Imaging in psoriatic arthritis: Established methods and emerging techniques","volume":"16","author":"Jin","year":"2024","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/rheumatology\/kex179","article-title":"Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: A systematic literature review","volume":"56","author":"Zabotti","year":"2017","journal-title":"Rheumatology"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Fassio, A., Matzneller, P., and Idolazzi, L. (2020). Recent Advances in Imaging for Diagnosis, Monitoring, and Prognosis of Psoriatic Arthritis. Front. Med., 7.","DOI":"10.3389\/fmed.2020.551684"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/RHU.0000000000000558","article-title":"Magnetic Resonance Imaging in Psoriatic Arthritis: A Descriptive Study of Indications, Features and Effect on Treatment Change","volume":"23","author":"Sheane","year":"2017","journal-title":"J. Clin. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Pennington, S.R., and FitzGerald, O. (2021). Early Origins of Psoriatic Arthritis: Clinical, Genetic and Molecular Biomarkers of Progression From Psoriasis to Psoriatic Arthritis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.723944"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/rheumatology\/keq105","article-title":"Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis","volume":"49","author":"Chandran","year":"2010","journal-title":"Rheumatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/ijd.ijd_167_24","article-title":"Biomarkers in Psoriasis: The Future of Personalised Treatment","volume":"69","author":"Kar","year":"2024","journal-title":"Indian J. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Mahendran, S.M., and Chandran, V. (2018). Exploring the Psoriatic Arthritis Proteome in Search of Novel Biomarkers. Proteomes, 6.","DOI":"10.3390\/proteomes6010005"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11306-023-02079-7","article-title":"Classifying patients with psoriatic arthritis according to their disease activity status using serum metabolites and machine learning","volume":"20","author":"Koussiouris","year":"2024","journal-title":"Metabolomics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.semarthrit.2007.03.004","article-title":"A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis","volume":"37","author":"Kivitz","year":"2007","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"204","DOI":"10.31138\/mjr.050424.ert","article-title":"2023 EULAR Recommendations for the Treatment of PsA: Advances and Pending Issues","volume":"35","author":"Sewerin","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_76","first-page":"S132","article-title":"Use of methotrexate in patients with psoriatic arthritis","volume":"28","author":"Ceponis","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheumatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: The diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Azuaga, A.B., Ram\u00edrez, J., and Ca\u00f1ete, J.D. (2023). Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054901"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","article-title":"Treatment of psoriatic arthritis with anti-TNF agents: A systematic review and meta-analysis of efficacy, effectiveness and safety","volume":"34","author":"Lemos","year":"2014","journal-title":"Rheumatol. Int."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jcpt.12045","article-title":"Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis","volume":"38","author":"Rey","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: An analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3899\/jrheum.141596","article-title":"Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study","volume":"43","author":"Behrens","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3899\/jrheum.151290","article-title":"Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials","volume":"43","author":"Combe","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: Results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety Assessment of Biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/art.39468","article-title":"Risk Factors for Targeted Fungal and Mycobacterial Infections in Patients Taking Tumor Necrosis Factor Inhibitors","volume":"68","author":"Salt","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides\u2014A follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: Results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): A double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","article-title":"Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","volume":"59","author":"Chandran","year":"2020","journal-title":"Rheumatology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5","volume":"59","author":"Mease","year":"2020","journal-title":"Rheumatology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: Results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2012-304154","article-title":"Secukinumab failure in Crohn\u2019s disease: The yeast connection?","volume":"62","author":"Colombel","year":"2013","journal-title":"Gut"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: Unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn\u2019s Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"iv16","DOI":"10.1093\/rheumatology\/keab385","article-title":"Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints","volume":"60","author":"Gracey","year":"2021","journal-title":"Rheumatology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ni.1698","article-title":"The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): A double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s10067-020-05057-9","article-title":"Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study","volume":"39","author":"Azuaga","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","article-title":"Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Bosch","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: Results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: Results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jlb.63.1.101","article-title":"Anti-inflammatory activities of cAMP-elevating agents: Enhancement of IL-10 synthesis and concurrent suppression of TNF production","volume":"63","author":"Eigler","year":"1998","journal-title":"J. Leukoc. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1124\/jpet.103.064691","article-title":"Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor","volume":"310","author":"Claveau","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: A phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: Results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_135","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13075-023-03027-5","article-title":"Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: Results from two phase 3 studies","volume":"25","author":"Baraliakos","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"105833","DOI":"10.1016\/j.jbspin.2024.105833","article-title":"Early methotrexate treatment for psoriatic arthritis prevention in psoriasis patients\u2014A retrospective cohort study","volume":"92","author":"Bar","year":"2025","journal-title":"Jt. Bone Spine"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/rheumatology\/keae257","article-title":"Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development","volume":"64","author":"Floris","year":"2025","journal-title":"Rheumatology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/art.43069","article-title":"Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis","volume":"77","author":"Poddubnyy","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Carmona-Rocha, E., Rusi\u00f1ol, L., and Puig, L. (2024). New and Emerging Oral\/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics, 16.","DOI":"10.20944\/preprints202401.0800.v1"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Yi, R.C., Akbik, M., Smith, L.R., Klionsky, Y., and Feldman, S.R. (2025). Therapeutic Advancements in Psoriasis and Psoriatic Arthritis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041312"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ard.2025.02.019","article-title":"Efficacy and safety of izokibep in patients with active psoriatic arthritis: A randomised, double-blind, placebo-controlled, phase 2 study","volume":"84","author":"Taylor","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"20406223211037846","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/rheumatology\/keae580","article-title":"Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial","volume":"64","author":"Kavanaugh","year":"2025","journal-title":"Rheumatology"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ard.2025.05.023","article-title":"Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: A randomised phase 2b study","volume":"84","author":"Kivitz","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and Safety of the TYK2\/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: Randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody","volume":"180","author":"Papp","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1093\/rheumatology\/kead022","article-title":"ROR\u03b3t inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating \u03b3\u03b4-T cells","volume":"62","author":"Mortier","year":"2023","journal-title":"Rheumatology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8151\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:23:45Z","timestamp":1763558625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":151,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14228151"],"URL":"https:\/\/doi.org\/10.3390\/jcm14228151","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}